Navigation Links
RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days
Date:5/8/2009

- Significant peak urine flow (Qmax) improvements within 2-6 hours of the first dose, according to published data -

CORONA, Calif., May 8 /PRNewswire-FirstCall/ -- RAPAFLO(TM) (silodosin), a new, uniquely selective alpha blocker for the treatment of the signs and symptoms of BPH, produces rapid improvements of both irritative and obstructive urinary symptoms that were sustained for 12 weeks, according to data published in the June issue of The Journal of Urology. RAPAFLO(TM) was developed and is manufactured by Watson Pharmaceuticals, a leader in generic and specialty branded pharmaceuticals.

In an analysis of data pooled from two Phase 3 studies, patients taking RAPAFLO(TM) demonstrated statistically significant symptom relief versus placebo within three to four days of starting treatment, and remained significant throughout the 12-week study period.

"The severity of urinary symptoms appears to depend in part on smooth muscle tone in the prostate and bladder neck, which is mediated by alpha 1A adrenoreceptors," said Leonard S. Marks, MD, author of the study and professor of urology at the Geffen School of Medicine, the University of California at Los Angeles. "The data indicate that RAPAFLO(TM) (silodosin) induces effective relaxation of the targeted prostatic muscle tissue, with a low incidence of vasodilatory and orthostatic effects. RAPAFLO(TM) (silodosin) is a fast acting, effective and safe treatment for the signs and symptoms associated with BPH."

BPH is the number one reason patients visit urologists and is characterized by urination problems, including decreased urine flow, more frequent urination and nocturia.

Clinical Trial Results

The new paper is a pooled analysis of two, 12-week, randomized, placebo-controlled, double-blind multi-center clinical trials involving 923 generally healthy men ages 50 or
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
2. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
3. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
4. USAID Provides $5M in Emergency Support as Swine Flu Spreads
5. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
6. Strativa Pharmaceuticals Provides Product Pipeline Update
7. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
8. VirtualScopics Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial
9. Savient Provides Update on Pegloticase BLA
10. USAID Provides Malaria Assistance to Zimbabwe
11. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... N.J. , Nov. 21, 2014  PTC Therapeutics, Inc. ... the 2014 Legend of Technology Award for Vision, Innovation, and ... Ph.D., Chief Executive Officer. This award recognizes an individual who ... New Jersey for several decades. ... Technology Award," stated Stuart Peltz , Ph.D., CEO of ...
(Date:11/21/2014)... and MELVILLE, N.Y. , Nov. 21, ... ), one of the world,s largest health care services ... ), the world,s largest provider of health care products ... practitioners, today announced that the companies have entered into ... most comprehensive service and product offerings to office-based medical ...
(Date:11/21/2014)... 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ) ... Officer, will be presenting at the 26 th Annual ... in New York . The formal presentation ... ET. In addition, Mr. Krakauer and Jorgen B. Hansen ... meetings during the day. An audio webcast ...
Breaking Medicine Technology:PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 2Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 4Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 5
... Johnson & Johnson Pharmaceutical,Research & Development, ... demonstrate doripenem (DORIBAX(TM), doripenem for injection), a,carbapenem ... in vitro against certain,strains of Enterobacteriaceae, including ... Enterobacteriaceae is a large group of ...
... annual ICAAC/IDSA meeting in Washington, D.C., WASHINGTON, ... nail,fungus, NB-002, has demonstrated a new topical approach ... diffusing through the skin that,surrounds the entire nail ... The data represent a unique approach to ...
Cached Medicine Technology:New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 2New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 3New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 4New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 5NanoBio Demonstrates New Topical Approach to Treating Nail Fungus That Circumvents Problems with Current Therapy 2NanoBio Demonstrates New Topical Approach to Treating Nail Fungus That Circumvents Problems with Current Therapy 3
(Date:11/23/2014)... 23, 2014 Today Zane Benefits, ... small businesses, announced their new on demand webinar ... Employer-Provided Health Insurance. , According to ... financial risk facing most American families. It is ... and large, when it comes to recruiting and ...
(Date:11/22/2014)... Recently, UWDress.com, a successful wedding dress shop, has ... in order to prepare for the wedding season. All ... off. , UWDress.com is a reliable company that has ... the new items -- formal wedding guest attire. This new ... including superstar and princess. As one of the leading companies ...
(Date:11/22/2014)... NY (PRWEB) November 22, 2014 ... Goods Administration (TGA) approved it for use “as ... approved and listed within the Therapeutic Goods (Listing) ... , Kyowa Hakko’s Setria® Glutathione will be ... biotech specialist that sources and imports fine chemicals ...
(Date:11/22/2014)... November 22, 2014 "My friend went ... caused by the machine," said an inventor from Cambria ... to go back a second time because the first ... , She developed the patent-pending MAMO EASY to offer ... The design saves the patient from the pain normally ...
(Date:11/22/2014)... York (PRWEB) November 22, 2014 Lipitor ... behalf of patients who allegedly developed Type 2 diabetes ... the federal multidistrict litigation now underway in U.S. District ... According to court documents, the litigation will convene its ... The Court has directed Lead Counsel for Plaintiffs and ...
Breaking Medicine News(10 mins):Health News:Zane Benefits, Inc. Announces New Webinar on The End of Employer-Provided Health Insurance Now Available On-Demand! 2Health News:Formal Wedding Guest Attire Added to UWDress.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3
... finds people who participated in a cardiac-rehab program after a ... as those of the same age and sex who had ... of the deaths that occurred among patients in their study ... ,The investigation involved about 1,800 patients. Nearly 60 percent ...
... low-glycemic index diet can lead to weight loss, reduced ... and cardiovascular disease. In low-GI foods, carbohydrates are low ... include white bread, refined breakfast cereals and concentrated sugars, ... to high levels. Carbs that release sugar more slowly ...
... A new study shows consuming foods or supplements containing the ... way to avoid Alzheimer’s disease // even if you carry ... the study researchers first bred mice to carry the gene ... Initially various environmental factors affecting the symptoms were studied but ...
... at an increased risk of dying from heart disease. ... more traits of metabolic syndrome have a 3.5-times higher ... syndrome is a group of metabolic risk factors including ... disorders, insulin resistance or glucose intolerance, and high-normal blood ...
... Mental decline usually associated with age, might affect women ... according to a recent study .// ,The ... worse cognitive performance and are at an increased risk ... cognitive impairment among women with pre-diabetes or diabetes was ...
... the number of Americans living with high blood pressure has ... pressure is defined // as having blood pressure of 140/90 ... their doctors at least twice that their blood pressure is ... ,However researchers say the study did not examine the reasons ...
Cached Medicine News:
The Gizmo male external catheter is a latex catheter that uses a single-sided adhesive strip....
... The Mentor Freedom Pak Seven ... packaged week's supply of Freedom ... kit all 100% latex-free ... wipes for your convenience and ...
Clear Advantage® is a premium 100% latex-free, self-adhering, one-piece catheter designed for maximum wear. It features aloe in the adhesive, and a kink-resistant nozzle designed to eliminate blo...
... all-silicone non-adhesive male external catheter is ... latex-related allergic reactions. It is designed ... change external catheters several times a ... catheter comes with an adjustable strap ...
Medicine Products: